MY134931A - Oral galantamine solution - Google Patents

Oral galantamine solution

Info

Publication number
MY134931A
MY134931A MYPI9904641A MY134931A MY 134931 A MY134931 A MY 134931A MY PI9904641 A MYPI9904641 A MY PI9904641A MY 134931 A MY134931 A MY 134931A
Authority
MY
Malaysia
Prior art keywords
solution
oral
galantamine
oral galantamine
galatamine
Prior art date
Application number
Inventor
Francois Marc Karel Jozef
Tony Mathilde Jozef Kempen
De Proost Eddy Andre Josee
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority to MYPI9904641 priority Critical patent/MY134931A/en
Publication of MY134931A publication Critical patent/MY134931A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE PRESENT INVENTION CONCERNS AN ORAL SOLUTION COMPRISING GALATAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF;ITS USE AND PROCESS OF PREPARING THE SAME.
MYPI9904641 1999-10-27 1999-10-27 Oral galantamine solution MY134931A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI9904641 MY134931A (en) 1999-10-27 1999-10-27 Oral galantamine solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI9904641 MY134931A (en) 1999-10-27 1999-10-27 Oral galantamine solution

Publications (1)

Publication Number Publication Date
MY134931A true MY134931A (en) 2008-01-31

Family

ID=45891002

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI9904641 MY134931A (en) 1999-10-27 1999-10-27 Oral galantamine solution

Country Status (1)

Country Link
MY (1) MY134931A (en)

Similar Documents

Publication Publication Date Title
BG106586A (en) Pyrazolopyramidines as therapeutic agents
AP9901534A0 (en) Pharmaceutical formulations.
GB2365772A (en) Factor
IL158107A0 (en) Human papillomaviruses vaccine
PL351261A1 (en) Derivatives of indigoid bisindoles
MXPA02009706A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts.
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002331313A1 (en) Use of l-polynucleotides and derivatives thereof for in vivo imaging
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
GB9907571D0 (en) Compounds
ZA200109206B (en) Preparation of substituted piperidin-4-ones.
GB0026837D0 (en) Process for the preparation of dental prosthesis
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
BG106031A (en) Prucalopride oral solution
BG104243A (en) Method for the synthesis of quinoline derivatives
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
MXPA02007903A (en) USE OF 2minus;METHYLminus;THIAZOLIDINminus;2,4minus;DICARBOXYLIC ACID (2minus;MTDC) AND OR PHYSIOLOGICALLY COMPATIBLE SALTS FOR TREATING AND OR PREVENTING CANCERS.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
BG106151A (en) Pharmaceutical complex
AU2662900A (en) One-pot process for the preparation of 5-sulfonyl-substituted benzotriazoles
HU0001891D0 (en) Medicament for the treatment of migraine